EA201991877A2 - 7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND METHODS OF APPLICATION - Google Patents

7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND METHODS OF APPLICATION

Info

Publication number
EA201991877A2
EA201991877A2 EA201991877A EA201991877A EA201991877A2 EA 201991877 A2 EA201991877 A2 EA 201991877A2 EA 201991877 A EA201991877 A EA 201991877A EA 201991877 A EA201991877 A EA 201991877A EA 201991877 A2 EA201991877 A2 EA 201991877A2
Authority
EA
Eurasian Patent Office
Prior art keywords
hexahydroimidazo
pyrido
methylbenzyl
pyrimidine
benzyl
Prior art date
Application number
EA201991877A
Other languages
Russian (ru)
Other versions
EA201991877A3 (en
Inventor
Мартин Стогниев
Джошуа Е. Аллен
Ричард С. Потторф
Бхаскара Рао Наллаганчу
Гэри Л. Олсон
Original Assignee
Онкосьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкосьютикс, Инк. filed Critical Онкосьютикс, Инк.
Publication of EA201991877A2 publication Critical patent/EA201991877A2/en
Publication of EA201991877A3 publication Critical patent/EA201991877A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится, по меньшей мере частично, к способу лечения. В одном варианте реализации способ лечения включает введение субъекту, нуждающемуся в таком лечении, первого терапевтического агента, включающего соединение (1)или его фармацевтически приемлемую соль, в комбинации со вторым терапевтическим агентом, при этом указанные первый терапевтический агент и второй терапевтический агент вводят одновременно или последовательно.The present invention relates, at least in part, to a method of treatment. In one embodiment, the treatment method comprises administering to a subject in need of such treatment a first therapeutic agent comprising a compound (1) or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent, wherein said first therapeutic agent and a second therapeutic agent are administered simultaneously or sequentially.

EA201991877A 2013-11-15 2014-09-12 7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND APPLICATIONS EA201991877A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904718P 2013-11-15 2013-11-15
PCT/US2014/048241 WO2015073072A1 (en) 2013-11-15 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one

Publications (2)

Publication Number Publication Date
EA201991877A2 true EA201991877A2 (en) 2020-01-31
EA201991877A3 EA201991877A3 (en) 2020-05-31

Family

ID=53057834

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991877A EA201991877A3 (en) 2013-11-15 2014-09-12 7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND APPLICATIONS

Country Status (2)

Country Link
EA (1) EA201991877A3 (en)
WO (1) WO2015073072A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3125898T1 (en) 2014-03-31 2020-07-31 The Scripps Research Institute Pharmacophore for trail induction
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
KR20240005186A (en) * 2015-01-30 2024-01-11 온코슈틱스 인코포레이티드 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
SG10202108306UA (en) 2016-01-29 2021-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
SG10202007520WA (en) 2016-03-02 2020-09-29 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
CN111153891B (en) * 2020-01-10 2023-03-31 贵州医科大学 Substituted benzimidazole PI3K alpha/mTOR double-target inhibitor and pharmaceutical composition and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642345A (en) * 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
CA2832342C (en) * 2011-04-29 2019-12-31 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

Also Published As

Publication number Publication date
WO2015073072A1 (en) 2015-05-21
EA201991877A3 (en) 2020-05-31

Similar Documents

Publication Publication Date Title
SG10201808496VA (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pytido[3.4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
EA201991877A2 (en) 7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND METHODS OF APPLICATION
EA201691008A1 (en) 7-BENZYL-4- (2-METHYLBENZIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PIRIDO [3,4-E] PYRIMIDIN-5 (1H) -OH SALTS AND APPLICATIONS
MX2023000782A (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy.
EA201590870A1 (en) AMINO-SUBSTITUTED IMIDAZO [1,2-a] Pyridinecarboxamides and their use
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
EA201490254A1 (en) COMBINED TREATMENT OF HEPATITIS C
EA201591702A1 (en) COMBINATION OF TWO ANTI-VIRAL PREPARATIONS FOR THE TREATMENT OF HEPATITIS C
PH12018502134A1 (en) Methods of treating pediatric cancers
EA201591924A1 (en) METHODS OF TREATING MALIGNANT TUMOR USING COMBINED THERAPY WITH COFFEE Q10
EA201691385A1 (en) Combined Cancer Therapy
MX2015013155A (en) Tetrandrine family pharmaceutical formulations and method.
WO2014186388A3 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
EA201500232A1 (en) Three (hetero) arylpyrazoles and their use
EA202190165A1 (en) 7-BENZYL-4- (2-METHYLBENZYL) -2,4,6,7,8,9-HEXAGYDROIMIDAZO [1,2-a] PYRIDO [3,4-e] PYRIMIDIN-5 (1H) -ON, ITS ANALOGUES AND SALTS AND METHODS OF THEIR APPLICATION IN THERAPY
TH1701000434A (en) [1,2,4] Triazolo [4,3-b] pyridazine for use in the therapy of multiplicative diseases.